EGFR-TKI AFTER DISEASE PROGRESSION WITH CENTRAL NERVOUS SYSTEM METASTASIS IN ADVANCED NON-SMALL CELL LUNG CANCER WITH EGFR MUTATIONS

被引：0
|
作者：
Kasahara, Kazuo [1 ]
Sone, Takashi [1 ]
Shibata, Kazuhiko [2 ]
Shirasaki, Hiroki [3 ]
Kita, Toshiyuki [4 ]
Sakai, Asao [5 ]
Nishikawa, Shingo [6 ]
Yoneda, Taro [1 ]
Kimura, Hideharu [1 ]
机构：
[1] Kanazawa Univ Hosp, Kanazawa, Ishikawa, Japan
[2] Kouseiren Takaoka Hosp, Takaoka, Toyama, Japan
[3] Fukui Ken Saiseika Hosp, Fukui, Japan
[4] Nho Kanazawa Med Ctr, Kanazawa, Ishikawa, Japan
[5] Keijyu Med Ctr, Nanao, Japan
[6] Kanazawa Social Insurance Hosp, Kanazawa, Ishikawa, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR tyrosine kinase inhibitor; EGFR mutation; Beyond Progressive Disease;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P3.11-045
引用
收藏
页码：S1210 / S1210
页数：1
相关论文
共 50 条
  • [21] Furmonertinib for EGFR-mutant advanced non-small cell lung cancer: a glittering diamond in the rough of EGFR-TKI
    Ding, Jianghua
    Ding, Xingjing
    Zeng, Jiao
    Liu, Xiaoqun
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [22] Sunitinib in treatment of advanced non-small cell lung cancer after failure of multiregimens of chemotherapy and EGFR-TKI
    Liu, X.
    Wang, W.
    Li, J.
    Tang, C.
    Yu, F.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Which is better, EGFR-TKI mono or combination for non-small cell lung cancer with mutated EGFR?
    Tanzawa, Shigeru
    Ishihara, Masashi
    Haruyama, Terunobu
    Ochiai, Ryosuke
    Sakamoto, Takahiko
    Honda, Takeshi
    Ota, Shuji
    Ichikawa, Yasuko
    Watanabe, Kiyotaka
    Seki, Nobuhiko
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 (06) : 2223 - 2229
  • [24] Serum carcinoembryonic antigen levels predicts the efficacy of EGFR-TKI in non-small cell lung cancer harboring EGFR mutations
    Zhang Yanwei
    Jin Bo
    Lou Yuqing
    Li Rong
    Zhang Xueyan
    Hu Song
    Han Baohui
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2016, 12 (01) : 254 - 258
  • [25] Mechanisms of EGFR-TKI induced cell death and resistance in EGFR mutant non-small cell lung cancer
    Ko, J.
    Kim, Y.
    Park, M.
    Cui, Z.
    Ahn, M.
    Park, K.
    EJC SUPPLEMENTS, 2008, 6 (09): : 29 - 30
  • [26] Effect of hydrothorax EGFR gene mutation and EGFR-TKI targeted therapy on advanced non-small cell lung cancer patients
    Zhou, Bo
    Nie, Jun
    Yang, Weidong
    Huang, Chenhong
    Huang, Ye
    Zhao, Hongfei
    ONCOLOGY LETTERS, 2016, 11 (02) : 1413 - 1417
  • [27] The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non-Small Cell Lung Cancer with EGFR Mutations
    Heon, Stephanie
    Yeap, Beow Y.
    Lindeman, Neal I.
    Joshi, Victoria A.
    Butaney, Mohit
    Britt, Gregory J.
    Costa, Daniel B.
    Rabin, Michael S.
    Jackman, David M.
    Johnson, Bruce E.
    CLINICAL CANCER RESEARCH, 2012, 18 (16) : 4406 - 4414
  • [28] TP53 Mutations Could Involve in EGFR-TKI Primary Resistance in Advanced Non-Small Cell Lung Cancer
    Li, X.
    Su, C.
    Ren, S.
    Zhao, C.
    Jiang, T.
    Chen, X.
    Li, J.
    Li, W.
    Gao, G.
    Zhou, F.
    Shao, Y.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2227 - S2227
  • [29] The role of EGFR-TKI for leptomeningeal metastases from non-small cell lung cancer
    Xu Yufen
    Song Binbin
    Chen Wenyu
    Liu Jialiang
    Yang Xinmei
    SPRINGERPLUS, 2016, 5
  • [30] Synergistic effect of metformin and EGFR-TKI in the treatment of non-small cell lung cancer
    Wang, Haocheng
    Yang, Xue
    Sun, Yang
    Li, Yanan
    Dong, Ya
    Shan, Dongfeng
    Yu, Zhuang
    TRANSLATIONAL CANCER RESEARCH, 2020, 9 (01) : 372 - 381
12345